NASDAQ Framework: Axsome Therapeutics Inc.

Biopharmaceutical company developing CNS disorder therapies 1.
1: Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. View Source
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company headquartered in New York, NY, that focuses on developing novel therapies for central nervous system (CNS) disorders 23. The company's commercial product portfolio includes Auvelity, indicated for major depressive disorder, and Sunosi, used for treating excessive daytime sleepiness in narcolepsy or obstructive sleep apnea 4. Additionally, Axsome is advancing a robust pipeline with late-stage assets such as AXS-05 for Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia 56. Founded in 2012, Axsome aims to address unmet medical needs in CNS conditions through its innovative therapeutic solutions 78.
2: Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. View Source3: Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY. View Source4: Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. View Source5: Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. View Source6: Axsome has three late-stage assets: AXS-07 for migraine, AXS-14 for fibromyalgia—2Q24 filing, and AXS-12 for narcolepsy filing post-second half data safety data, which can collectively drive ~$1 billion in sales by 2030 with a 60-65% probability of success. View Source7: Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. View Source8: Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY. View Source
UNKNOWN

The provided facts do not specify whether the founders of Axsome Therapeutics Inc. are still leading the company or are heavily involved. The information includes details about the current management team and their backgrounds but does not mention the founders' current roles or involvement [fERROR]UNKNOWN

The provided facts do not specify whether the founders of Axsome Therapeutics Inc. are still leading the company or are heavily involved. The information includes details about the current management team and their backgrounds but does not mention the founders' current roles or involvement [fERROR][fERROR]UNKNOWN

The provided facts do not specify whether the founders of Axsome Therapeutics Inc. are still leading the company or are heavily involved. The information includes details about the current management team and their backgrounds but does not mention the founders' current roles or involvement [fERROR][fERROR][fERROR]UNKNOWN

The provided facts do not specify whether the founders of Axsome Therapeutics Inc. are still leading the company or are heavily involved. The information includes details about the current management team and their backgrounds but does not mention the founders' current roles or involvement [fERROR][fERROR][fERROR].
MEDIUM RISK

Axsome Therapeutics Inc. presents a medium risk financial situation. The company has a high debt-to-equity ratio of 1.32, indicating a significant reliance on borrowed funds, which raises concerns about financial leverage 9. Additionally, Axsome's net margin is -91.14%, and its return on equity (ROE) is -40.81%, both of which are below industry standards and suggest challenges in achieving profitability and efficient capital utilization 1011. However, the company has a diversified CNS portfolio with promising late-stage assets and two marketed drugs, Auvelity and Sunosi, which are expected to drive significant revenue growth 121314. Despite the financial challenges, the potential for substantial upside from its pipeline and existing products provides a balanced outlook, justifying a medium risk classification.
9: Debt Management: Axsome Therapeutics's debt-to-equity ratio stands notably higher than the industry average, reaching 1.32. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage. View Source10: Net Margin: Axsome Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -91.14%, the company may encounter challenges in effective cost control. View Source11: Return on Equity (ROE): Axsome Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -40.81%, the company may face hurdles in achieving optimal financial returns. View Source12: Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York. View Source13: Needham writes that Axsome Therapeutics’ diversified CNS portfolio will help grow the risk-adjusted topline by 8-10x in five years. View Source14: The analyst anticipates an upside for Axsome Therapeutics on its two marketed drugs, Auvelity for major depressive disorder and Sunosi for excessive daytime sleepiness. View Source
NO

The provided facts do not indicate that Axsome Therapeutics Inc. is launching any new product offerings. The information mentions the company's existing commercial products, Auvelity and Sunosi, and its pipeline assets, but there is no specific mention of new product launches [fERROR]NO

The provided facts do not indicate that Axsome Therapeutics Inc. is launching any new product offerings. The information mentions the company's existing commercial products, Auvelity and Sunosi, and its pipeline assets, but there is no specific mention of new product launches [fERROR][fERROR]NO

The provided facts do not indicate that Axsome Therapeutics Inc. is launching any new product offerings. The information mentions the company's existing commercial products, Auvelity and Sunosi, and its pipeline assets, but there is no specific mention of new product launches [fERROR][fERROR].
Axsome Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on advancing its diversified CNS portfolio to drive significant revenue growth. The company is poised to leverage its late-stage assets, including AXS-05 for Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, which collectively have the potential to generate approximately $1 billion in sales by 2030 [fERROR]Axsome Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on advancing its diversified CNS portfolio to drive significant revenue growth. The company is poised to leverage its late-stage assets, including AXS-05 for Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, which collectively have the potential to generate approximately $1 billion in sales by 2030 [fERROR]. Additionally, Axsome aims to expand the market reach of its two marketed drugs, Auvelity and Sunosi, which are expected to contribute to an 8-10x growth in the risk-adjusted topline over the next five years [fERROR]Axsome Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on advancing its diversified CNS portfolio to drive significant revenue growth. The company is poised to leverage its late-stage assets, including AXS-05 for Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, which collectively have the potential to generate approximately $1 billion in sales by 2030 [fERROR]. Additionally, Axsome aims to expand the market reach of its two marketed drugs, Auvelity and Sunosi, which are expected to contribute to an 8-10x growth in the risk-adjusted topline over the next five years [fERROR][fERROR]Axsome Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on advancing its diversified CNS portfolio to drive significant revenue growth. The company is poised to leverage its late-stage assets, including AXS-05 for Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, which collectively have the potential to generate approximately $1 billion in sales by 2030 [fERROR]. Additionally, Axsome aims to expand the market reach of its two marketed drugs, Auvelity and Sunosi, which are expected to contribute to an 8-10x growth in the risk-adjusted topline over the next five years [fERROR][fERROR]. This strategic focus on both pipeline advancement and market expansion underscores Axsome's commitment to addressing unmet medical needs in CNS conditions [fERROR]Axsome Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on advancing its diversified CNS portfolio to drive significant revenue growth. The company is poised to leverage its late-stage assets, including AXS-05 for Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, which collectively have the potential to generate approximately $1 billion in sales by 2030 [fERROR]. Additionally, Axsome aims to expand the market reach of its two marketed drugs, Auvelity and Sunosi, which are expected to contribute to an 8-10x growth in the risk-adjusted topline over the next five years [fERROR][fERROR]. This strategic focus on both pipeline advancement and market expansion underscores Axsome's commitment to addressing unmet medical needs in CNS conditions [fERROR][fERROR]Axsome Therapeutics Inc.'s product roadmap and expansion strategy for 2024 through to 2026 focuses on advancing its diversified CNS portfolio to drive significant revenue growth. The company is poised to leverage its late-stage assets, including AXS-05 for Alzheimer's disease agitation, AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, which collectively have the potential to generate approximately $1 billion in sales by 2030 [fERROR]. Additionally, Axsome aims to expand the market reach of its two marketed drugs, Auvelity and Sunosi, which are expected to contribute to an 8-10x growth in the risk-adjusted topline over the next five years [fERROR][fERROR]. This strategic focus on both pipeline advancement and market expansion underscores Axsome's commitment to addressing unmet medical needs in CNS conditions [fERROR][fERROR].